Synlogic Inc (SYBX)

$1.12 -0.02 (-1.75%)
Market Cap 13.34M
Revenue (ttm) 10,000.00
Net Income (ttm) -23.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233,600.01%
Debt to Equity Ratio 0.00
Volume 5,200
Avg Vol 44,734
Day's Range N/A - N/A
Shares Out 11.70M
Stochastic %K 0%
Beta 0.39
Analysts Strong Buy
Price Target $1.00

Company Profile

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 659 2802
Address:
PO Box 30, Winchester, United States
CollateralCallC
CollateralCallC Dec. 26 at 4:05 PM
$SYBX Conditions are shifting toward markets rewarding operational proof over narrative ambition. Balance sheet resilience remains an underappreciated swing factor. Evidence of repeatability is likely to change market tone. The forward path ultimately depends on disciplined delivery.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 12:21 PM
$SYBX RSI: 52.27, MACD: -0.1004 Vol: 0.17, MA20: 1.19, MA50: 1.49 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 5:07 PM
$VCIG $AKBA $JAGX $IFRX 1.62 FROM BELOVED $SYBX ETC CODING 1.62 FOR ENTIRE MARKETS
0 · Reply
NoEmotionzTrade
NoEmotionzTrade Oct. 30 at 9:16 PM
QCLS just unlocked the kind of narrative that goes parabolic Quantum class compute + crypto infrastructure = a sector the market doesn’t know how to price — yet. One spark and this float is toast. This is the real sleeper. $ZVSA $SYBX $GTII $ETON
0 · Reply
Doozio
Doozio Oct. 25 at 1:45 PM
$SYBX thin to win. How can it be euphoric wen jabronis where going back to cash again worried about 🚽 seats during 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Oct. 15 at 10:09 PM
$SYBX ghetto banging cup n handle MAMA as its thin to win wen it spreads on the DLO 🐒🍌🧠⏰♾️
0 · Reply
Quantumup
Quantumup Sep. 4 at 3:37 PM
H.C. Wainwright y'day reiterated $TVTX Buy/$47. $SYBX $NVS $AHKSY $VRTX #ICIEM25 H.C. Wainwright said that in finds the long-term HCU data presented at the Int'l Congress of Inborn Errors of Metabolism as 'Highly Encouraging' w/ 'Clinically Meaningful Reductions in Key Metabolites Sustained Over Approximately One Year of Treatment with Pegtibatinase.' H.C. Wainwright said in its note to investors:
0 · Reply
smoketuna
smoketuna Sep. 4 at 2:28 PM
$SYBX 81% with 🎯 TunaSignal.ai score! while price $1.51 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 11:15 AM
$SYBX Brilliant piece that captures SYBX's situation perfectly. So if you want to update your understanding of SYBX or get to know SYBX better, this is essential reading. https://beyondspx.com/quote/SYBX/synlogic-s-strategic-crossroads-unlocking-value-from-a-pivotal-shift-sybx#analysis
0 · Reply
AsymmetricVentures
AsymmetricVentures Jul. 18 at 5:51 PM
Cable Car Cap controlled 9+% of $LITS as of their last 13F. With that Digital Treasury deal out of the way ... they can focus on $SYBX, where they own 4.5+% per their last 13F
0 · Reply
Latest News on SYBX
Synlogic Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:35 PM EST - 1 year ago

Synlogic Reports Third Quarter 2024 Financial Results

Synlogic Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports Second Quarter 2024 Financial Results

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports First Quarter 2024 Financial Results

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Synlogic Adopts Limited Duration Stockholders Rights Plan

Feb 20, 2024, 12:15 PM EST - 2 years ago

Synlogic Adopts Limited Duration Stockholders Rights Plan

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Feb 8, 2024, 4:15 PM EST - 2 years ago

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Feb 2, 2024, 12:00 PM EST - 2 years ago

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic Provides Corporate Update and Outlook for 2024

Jan 4, 2024, 7:00 AM EST - 2 years ago

Synlogic Provides Corporate Update and Outlook for 2024

Synlogic Announces Contract with the Air Force Research Lab

Dec 27, 2023, 7:00 AM EST - 2 years ago

Synlogic Announces Contract with the Air Force Research Lab

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Dec 7, 2023, 7:00 AM EST - 2 years ago

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Oct 3, 2023, 4:15 PM EDT - 2 years ago

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Sep 29, 2023, 7:00 AM EDT - 2 years ago

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Sep 28, 2023, 11:15 AM EDT - 2 years ago

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Synlogic Announces Reverse Stock Split

Sep 27, 2023, 12:30 PM EDT - 2 years ago

Synlogic Announces Reverse Stock Split

Synlogic to Participate in Chardan's Genetic Medicines Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Synlogic to Participate in Chardan's Genetic Medicines Conference

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

Sep 19, 2023, 11:00 AM EDT - 2 years ago

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

Jul 11, 2023, 7:00 AM EDT - 2 years ago

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

Jun 28, 2023, 7:00 AM EDT - 2 years ago

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

Jun 27, 2023, 7:00 AM EDT - 2 years ago

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

Jun 8, 2023, 6:45 AM EDT - 2 years ago

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Jun 5, 2023, 6:45 AM EDT - 2 years ago

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

May 24, 2023, 6:35 AM EDT - 2 years ago

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Synlogic to Present at the Jefferies Global Healthcare Conference

May 23, 2023, 6:50 AM EDT - 2 years ago

Synlogic to Present at the Jefferies Global Healthcare Conference

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 6:50 AM EDT - 2 years ago

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

May 9, 2023, 6:50 AM EDT - 2 years ago

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Mar 29, 2023, 6:40 AM EDT - 3 years ago

Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

Mar 28, 2023, 6:52 AM EDT - 3 years ago

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Mar 20, 2023, 6:55 AM EDT - 3 years ago

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Mar 7, 2023, 6:57 AM EST - 3 years ago

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

Jan 24, 2023, 6:57 AM EST - 3 years ago

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

Jan 19, 2023, 6:58 AM EST - 3 years ago

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

Synlogic Provides Corporate Update and Outlook for 2023

Jan 5, 2023, 6:58 AM EST - 3 years ago

Synlogic Provides Corporate Update and Outlook for 2023

Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

Jan 3, 2023, 6:58 AM EST - 3 years ago

Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Dec 15, 2022, 6:59 AM EST - 3 years ago

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Nov 30, 2022, 4:15 PM EST - 3 years ago

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 6:59 AM EST - 3 years ago

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

Oct 18, 2022, 6:59 AM EDT - 3 years ago

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Aug 23, 2022, 7:00 AM EDT - 3 years ago

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 1:41 PM EDT - 3 years ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2022 Results - Earnings Call Transcript

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Aug 11, 2022, 7:05 AM EDT - 3 years ago

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

DNA

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 11, 2022, 6:58 AM EDT - 3 years ago

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Jul 12, 2022, 7:00 AM EDT - 3 years ago

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic Announces Appointment of General Counsel and Corporate Secretary

Jun 29, 2022, 7:00 AM EDT - 3 years ago

Synlogic Announces Appointment of General Counsel and Corporate Secretary

Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

Jun 28, 2022, 7:00 AM EDT - 3 years ago

Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

Jun 21, 2022, 7:00 AM EDT - 3 years ago

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2022 Results - Earnings Call Transcript

May 12, 2022, 12:54 PM EDT - 4 years ago

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2022 Results - Earnings Call Transcript

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022, 7:00 AM EDT - 4 years ago

Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

CollateralCallC
CollateralCallC Dec. 26 at 4:05 PM
$SYBX Conditions are shifting toward markets rewarding operational proof over narrative ambition. Balance sheet resilience remains an underappreciated swing factor. Evidence of repeatability is likely to change market tone. The forward path ultimately depends on disciplined delivery.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 12:21 PM
$SYBX RSI: 52.27, MACD: -0.1004 Vol: 0.17, MA20: 1.19, MA50: 1.49 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 5:07 PM
$VCIG $AKBA $JAGX $IFRX 1.62 FROM BELOVED $SYBX ETC CODING 1.62 FOR ENTIRE MARKETS
0 · Reply
NoEmotionzTrade
NoEmotionzTrade Oct. 30 at 9:16 PM
QCLS just unlocked the kind of narrative that goes parabolic Quantum class compute + crypto infrastructure = a sector the market doesn’t know how to price — yet. One spark and this float is toast. This is the real sleeper. $ZVSA $SYBX $GTII $ETON
0 · Reply
Doozio
Doozio Oct. 25 at 1:45 PM
$SYBX thin to win. How can it be euphoric wen jabronis where going back to cash again worried about 🚽 seats during 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Oct. 15 at 10:09 PM
$SYBX ghetto banging cup n handle MAMA as its thin to win wen it spreads on the DLO 🐒🍌🧠⏰♾️
0 · Reply
Quantumup
Quantumup Sep. 4 at 3:37 PM
H.C. Wainwright y'day reiterated $TVTX Buy/$47. $SYBX $NVS $AHKSY $VRTX #ICIEM25 H.C. Wainwright said that in finds the long-term HCU data presented at the Int'l Congress of Inborn Errors of Metabolism as 'Highly Encouraging' w/ 'Clinically Meaningful Reductions in Key Metabolites Sustained Over Approximately One Year of Treatment with Pegtibatinase.' H.C. Wainwright said in its note to investors:
0 · Reply
smoketuna
smoketuna Sep. 4 at 2:28 PM
$SYBX 81% with 🎯 TunaSignal.ai score! while price $1.51 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 11:15 AM
$SYBX Brilliant piece that captures SYBX's situation perfectly. So if you want to update your understanding of SYBX or get to know SYBX better, this is essential reading. https://beyondspx.com/quote/SYBX/synlogic-s-strategic-crossroads-unlocking-value-from-a-pivotal-shift-sybx#analysis
0 · Reply
AsymmetricVentures
AsymmetricVentures Jul. 18 at 5:51 PM
Cable Car Cap controlled 9+% of $LITS as of their last 13F. With that Digital Treasury deal out of the way ... they can focus on $SYBX, where they own 4.5+% per their last 13F
0 · Reply
Chrissytina
Chrissytina Jul. 16 at 3:02 PM
$SYBX 138,124 volume 😳 that’s a lot for this company!
0 · Reply
jaydilks
jaydilks Jul. 16 at 2:25 PM
$DNA Old news release might have validity why $17 Mill Market Cap, $SYBX stock is suddenly off life support. My guess would be GOUT Therapeutic. I’d own DNA over SYBX because of the leverage DNA has in ownership and IP. (Speculation Alert). Take it with a grain of Salt. https://www.prnewswire.com/news-releases/synlogic-announces-synthetic-biotic-for-gout-developed-in-partnership-with-ginkgo-bioworks-301603915.html
2 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 4:06 PM
$SYBX DUE TO THIS!*
1 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 3:56 PM
$ALTO $SYBX !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 3:56 PM
$SYBX !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 15 at 10:31 AM
$ALTO working on something for u some what soon $SYBX need to change foew things on sybx side note timer issue
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 9 at 10:16 PM
$SYBX $SBFM making changes for u both
1 · Reply